PT-141, also called bremelanotide, is a melanocortin-receptor agonist studied for sexual desire and arousal. The FDA-approved product, Vyleesi, is an injection for acquired, generalized HSDD in certain premenopausal women—not a nasal spray. PT-141 nasal spray is typically compounded and should only be used after licensed clinician review.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What is PT-141 nasal spray?
PT-141 nasal spray is a compounded prescription form of bremelanotide, a peptide that acts on melanocortin receptors in the central nervous system. The key point: the studied and FDA-approved bremelanotide product is an injection, while nasal spray is a compounded formulation with a different evidence base.
PT-141, bremelanotide, and Vyleesi: how the names differ
PT-141 is the research name. Bremelanotide is the generic drug name. Vyleesi is the brand name for FDA-approved bremelanotide injection, a subcutaneous injection approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women who have not had sexual desire problems in the past 1.
At Chia, we offer PT-141 nasal spray as a compounded prescription option after online evaluation by a licensed US provider. For a deeper background on the molecule itself, see our guide to PT-141 uses, evidence, safety, and dosing questions.
Why the nasal-spray form is different from the FDA-approved injection
Route matters. A subcutaneous injection places medication under the skin, while a nasal spray must be absorbed through the nasal lining. That can affect absorption, timing, dose precision, and how much evidence applies to the exact product being used.
Quick facts about PT-141 nasal spray
Bremelanotide has one FDA-approved form: Vyleesi injection. PT-141 nasal spray is best understood as a prescription compounded option, not as a proven substitute for the labeled injection.
- Approved form: Vyleesi subcutaneous injection for acquired, generalized HSDD in certain premenopausal women 1.
- Compounded form: PT-141 nasal spray by prescription through a licensed clinician and compounding pharmacy.
- Main studied use: acquired, generalized HSDD in premenopausal women; phase 3 trials enrolled 714 and 723 participants in two completed studies 6, 7.
- Key safety issue: nausea, flushing, headache, and temporary blood-pressure increase with heart-rate decrease 1.
- Best next step: clinician evaluation rather than self-sourcing from research-use peptide sellers.
Does PT-141 work as a nasal spray?
The honest answer is that human evidence is strongest for injectable bremelanotide, not compounded nasal spray. Nasal spray may be prescribed by clinicians in some settings, but its outcomes are not established to the same degree as the FDA-reviewed injectable program.
What human studies show about bremelanotide overall
In two phase 3 randomized trials called RECONNECT, bremelanotide improved sexual desire scores and reduced distress related to low desire compared with placebo in premenopausal women with HSDD 2. These trials support the active ingredient as studied, but individual results vary and the same evidence should not be treated as proof that every formulation works the same way.
Earlier dose-finding research also evaluated bremelanotide in premenopausal women with female sexual dysfunction, including female sexual interest/arousal disorder and HSDD 5. Across the development program, side effects mattered: nausea was common, and flushing, headache, and administration-site reactions were also reported 4.
Why evidence is strongest for the approved injectable product
The FDA label is based on the injectable product, including its route, device, dose, and clinical trials 1. That matters because a compounded nasal spray is a different formulation and is not reviewed by FDA for safety, effectiveness, or manufacturing quality in the same way.
What is known and not known about compounded nasal sprays
A clinician may consider compounded PT-141 nasal spray when the patient’s history, goals, and risk profile make it reasonable. What is not known: whether a given compounded nasal formulation produces the same exposure, timing, or results as the studied injectable product. This is why prescription review and follow-up matter.
3-min quiz
Considering PT-141 nasal spray?
Chia offers PT-141 nasal spray from $159/mo after a licensed provider reviews your health history and goals. A prescription requires medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
How does PT-141 affect sexual desire?
PT-141 works through brain signaling, not mainly through blood flow. It activates melanocortin pathways that are involved in sexual motivation and arousal, which makes it different from medications like sildenafil or tadalafil.
Melanocortin receptors and central nervous system signaling
Bremelanotide is a melanocortin-receptor agonist. It is thought to act through MC3 and MC4 receptor pathways in the central nervous system, including brain circuits tied to sexual desire and arousal 3. This mechanism is one reason it has been studied for low libido and HSDD.
How PT-141 differs from sildenafil and other PDE5 inhibitors
PDE5 inhibitors such as sildenafil and tadalafil mainly help the blood-flow part of sexual response. PT-141 is different because it targets central nervous system sexual desire pathways rather than only vascular smooth muscle 3. That does not make it better for every person; it means it is aimed at a different problem.
Why desire, arousal, and erectile function are not the same problem
Low desire, trouble with arousal, pain, orgasm concerns, erectile dysfunction, relationship stress, medication effects, and hormone changes can overlap. A clinician may review mental health, cardiovascular risk, medications, pregnancy concerns, menopause status, and whether symptoms fit acquired, generalized HSDD before considering bremelanotide.
How long does PT-141 nasal spray take to kick in?
Timing data are clearest for Vyleesi injection, not compounded nasal spray. Nasal timing can vary by formulation, nasal absorption, congestion, technique, and patient factors, so online timing schedules should not be copied as instructions.
What official Vyleesi labeling says about timing for the approved injection
The FDA label for Vyleesi describes an approved 1.75 mg subcutaneous injection used as needed, at least 45 minutes before anticipated sexual activity, with limits on frequency in the label 1. That is label information for the approved injection, not dosing advice for PT-141 nasal spray.
Why compounded nasal timing can vary by formulation and patient
Nasal sprays depend on local absorption through the nose. Allergies, nasal irritation, recent illness, other nasal products, and the specific compounded formulation can all matter. Because compounded PT-141 nasal spray is not FDA-approved, it does not have FDA-reviewed onset data in the same way the injectable product does.
Why patients should not copy online dosing or timing schedules
Copying a forum schedule can raise the risk of nausea, flushing, blood-pressure changes, or drug interactions. If you want to understand dosing concepts without turning internet posts into instructions, our PT-141 dosage chart guide explains what research can and cannot tell patients.
PT-141 nasal spray vs Vyleesi injection: what is the difference?
The main difference is route and regulatory status: Vyleesi is the FDA-approved injectable bremelanotide product, while PT-141 nasal spray is a compounded prescription formulation. Both require clinician judgment, but the evidence is not equal.
| Feature | Vyleesi injection | Compounded PT-141 nasal spray |
|---|---|---|
| Active ingredient | Bremelanotide | PT-141/bremelanotide |
| Route | Subcutaneous injection | Nasal spray |
| FDA status | FDA-approved for acquired, generalized HSDD in certain premenopausal women 1 | Not FDA-approved; compounded by prescription when clinically appropriate |
| Evidence strength | Strongest human evidence; phase 3 trials and FDA label | More limited formulation-specific evidence |
| Absorption and dose precision | Defined labeled injection product | May vary by formulation and nasal absorption |
| Common risks | Nausea, flushing, headache, injection-site reactions, temporary blood-pressure changes 1, 4 | May share similar active-ingredient risks; formulation-specific data are more limited |
| Prescription requirement | Prescription required | Prescription required through a licensed clinician |
What side effects and risks should patients know?
Nausea is one of the most important PT-141 risks to plan for, and cardiovascular review matters. Benefits and risks should be weighed together, especially for people with heart disease, uncontrolled hypertension, complex medication lists, or unclear sexual-health symptoms.
Common adverse effects reported in clinical trials
Across the bremelanotide clinical development program, adverse events included nausea, flushing, headache, vomiting, and administration-site reactions for the injectable product 4. The FDA label also notes focal hyperpigmentation, including changes affecting the face, gums, and breasts, reported more often in people with darker skin and with more frequent use 1.
Blood pressure and heart-rate warnings
The FDA label states that bremelanotide can temporarily increase blood pressure and reduce heart rate after dosing 1. Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease 1.
Who may not be eligible
A clinician may decide PT-141 is not appropriate for someone with cardiovascular disease, uncontrolled high blood pressure, pregnancy concerns, certain medication use, severe nausea history, or symptoms better explained by another condition. Subgroup analyses from RECONNECT add useful human data, but they should not be used to broaden claims beyond studied populations 8.
When to contact a clinician
Patients should contact a clinician promptly for severe or persistent nausea, chest pain, fainting, marked blood-pressure symptoms, allergic symptoms, mood concerns, or sexual-health symptoms that are new, painful, or distressing. For a broader overview, see our guide to peptide side effects.
Do you need a prescription for PT-141 nasal spray?
Yes, PT-141 nasal spray for human use should be obtained by prescription. Prescription review is not just a legal step; it is how a clinician checks whether the medication fits your symptoms, health history, and risk factors.
Why prescription review matters
Sexual desire concerns can come from many causes, including stress, depression, relationship strain, pain, menopause, medication effects, low testosterone, thyroid disease, or cardiovascular disease. A prescription visit helps separate a medication-fit question from a broader health question.
Risks of research-use peptides and unverified sellers
Products sold as “research use only” are not meant for human treatment. They may lack reliable sterility, potency, identity, storage, and prescription oversight. If a seller offers PT-141 for human use without a prescription, that is a reason to pause.
What a clinician may review before prescribing
A clinician may review your blood pressure, heart history, medications, pregnancy status, sexual-health history, and whether the concern is desire, arousal, erectile function, pain, or orgasm. Our guide on how to get a peptide prescription safely explains what legitimate review usually includes.
PT-141 nasal spray at Chia: clinician-reviewed access online
At Chia, PT-141 is offered as a nasal spray, with plans currently starting at $159/mo. Care starts online with a health questionnaire, then a licensed US provider reviews your information and prescribes only when clinically appropriate.
Chia’s PT-141 offering: nasal spray from $159/mo
Chia offers PT-141 in nasal spray form only. We do not present it as the same as Vyleesi injection, and we do not promise outcomes. The goal is to make clinician-reviewed access clearer for patients who are already looking into PT-141 and want a licensed route.
How online evaluation works
You complete a short online health questionnaire. A licensed provider reviews your history, goals, medications, and risk factors. If prescribed, dosing is provider-guided and can be adjusted over time through the patient portal.
State-licensed 503A compounding pharmacy and home shipping
When a prescription is appropriate, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door. This licensed-provider and licensed-pharmacy path is different from buying “research peptide” products online.
When the Spark protocol may be relevant
Chia also offers the Spark protocol, which includes PT-141 nasal spray and currently starts at $159/mo. A provider still must review eligibility, and a prescription is never guaranteed.
Where can I get PT-141 nasal spray safely?
The safer route is a licensed clinician and a legitimate pharmacy, not a no-prescription peptide seller. For PT-141 nasal spray, that usually means a telehealth clinic or an in-person clinician who can prescribe through an appropriate pharmacy.
Licensed telehealth clinic
A licensed telehealth clinic can review your history online, decide whether PT-141 is appropriate, and coordinate pharmacy fulfillment if prescribed. If you are comparing options, our guide on how to buy PT-141 online safely lists practical checks to use.
Traditional clinician and pharmacy route
An in-person clinician can also evaluate sexual-health symptoms and prescribe when appropriate. This may be useful if symptoms are complex, painful, sudden, linked to a new medication, or tied to cardiovascular or hormone concerns.
What to avoid when shopping online
- Sellers that do not require a prescription for human use.
- Products labeled “research use only” or “not for human consumption.”
- Sites that promise sexual results or ignore side effects.
- Vague sourcing, no pharmacy information, or no way to contact a licensed clinician.
- Online dosing schedules presented as one-size-fits-all instructions.
Questions to ask before starting
- Is my main concern desire, arousal, erectile function, pain, or something else?
- Do I have blood-pressure or heart-risk factors that matter for bremelanotide?
- Which side effects should I watch for, and how do I contact the care team?
- Is this product compounded, and which licensed pharmacy dispenses it?
- What follow-up is available if it does not fit my goals or causes side effects?
3-min quiz
Start with a licensed review
If you are considering PT-141 nasal spray, Chia can review your health history online and help determine whether treatment is appropriate. Plans for PT-141 nasal spray currently start at $159/mo. A prescription requires medical evaluation and is not guaranteed; compounded drugs are not FDA-approved.
FAQ
Bremelanotide has human trial evidence for acquired, generalized HSDD in certain premenopausal women, but that evidence is strongest for the FDA-approved injection. PT-141 nasal spray is a compounded prescription form, and outcomes are not established in the same way for compounded formulations.
Use in men is outside the FDA-approved indication for Vyleesi. Some clinicians may discuss off-label use, but it requires individualized review, especially if the concern is erectile dysfunction, cardiovascular risk, medication effects, or low testosterone.
No. The FDA-approved bremelanotide product is Vyleesi, a subcutaneous injection. PT-141 nasal spray is a compounded prescription formulation and is not FDA-approved.
PT-141 and bremelanotide refer to the active peptide. Vyleesi is the FDA-approved injectable brand product. A compounded PT-141 nasal spray should not be treated as the same product because route, formulation, absorption, and evidence base can differ.
That depends on the person. Sildenafil and tadalafil are PDE5 inhibitors that work mainly through blood flow, while PT-141 works through central nervous system pathways. A clinician should review cardiovascular risk, blood pressure, medications, and the sexual-health concern before combining therapies.
PT-141 nasal spray for human use should require a prescription. Avoid products labeled for research use or sellers that do not require clinician review.
Do not copy online frequency schedules. The FDA label provides limits for the approved injection, but compounded nasal spray needs provider-guided instructions based on the exact prescription, health history, and side effects.
Contact your prescribing clinician, especially if symptoms are severe, persistent, or paired with dizziness, chest pain, fainting, or blood-pressure symptoms. Do not increase use to push through side effects.
References
- 1.U.S. Food and Drug Administration. Vyleesi (bremelanotide) injection prescribing information. 2019.
- 2.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
- 3.Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003.
- 4.Clayton AH, Kingsberg SA, Portman D, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women's Health. 2022.
- 5.Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health. 2016.
- 6.ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder, NCT02338960. 2021.
- 7.ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder, NCT02333071. 2021.
- 8.Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women's Health. 2022.
- 9.ClinicalTrials.gov. Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder, NCT01382719. 2018.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
